Could medicines already used to treat ADHD and type 2 diabetes offer new possibilities for protecting memory in Alzheimer’s disease?

Researchers are investigating whether atomoxetine and metformin could influence biological processes associated with cognitive decline. This article examines the scientific rationale, emerging evidence and important limitations of these approaches—and why promising research should not be mistaken for proven treatment.